Storm Therapeutics closed a $56 million Series C to drive STC-15 into Phase 2 evaluation across sarcoma indications. The RNA epigenetics program targets METTL3, an enzyme involved in mRNA methylation, and the company says the trial is designed to generate Phase 2 results across multiple indications. Storm reported that STC-15 demonstrated durable tumor regression across sarcoma subtypes in Phase 1 (NCT0558411), and it has now treated the first patient in Phase 2. The company also points to a potential fit with accelerated approval pathways, depending on future outcomes. For sarcoma—where options are constrained and many tumors lack classic targets—METTL3 inhibition could become a meaningful new mechanism if clinical signals hold in Phase 2.